<?xml version="1.0" encoding="UTF-8"?>
<p>The current dengue clinical classification, proposed by WHO in 2009, includes central nervous system (CNS) involvement in the definition of SD requiring intensive care and supportive management [
 <xref rid="B57-viruses-12-00671" ref-type="bibr">57</xref>]. DENV infections in endemic regions have long been recognized for their neuronal manifestations [
 <xref rid="B62-viruses-12-00671" ref-type="bibr">62</xref>,
 <xref rid="B63-viruses-12-00671" ref-type="bibr">63</xref>], where frequency ranges from 0.5% to 21% [
 <xref rid="B60-viruses-12-00671" ref-type="bibr">60</xref>], and the incidence rate for strokes is less than 1% [
 <xref rid="B30-viruses-12-00671" ref-type="bibr">30</xref>,
 <xref rid="B37-viruses-12-00671" ref-type="bibr">37</xref>]. Generally, patients develop early non-specific symptoms such as fever, headache, myalgia and exanthema, with initial and transient resolution, followed by recrudescence of headache, fever and neurological symptoms onset [
 <xref rid="B23-viruses-12-00671" ref-type="bibr">23</xref>], similar to our patient 1, who, in recovery phase, progressed to neuronal impairment.
</p>
